Correction to: J ImmunoTher Cancer (2019) 7:288

https://doi.org/10.1186/s40425-019-0778-7

Following publication of the original article [1], the authors have reported that Fig. 2 and Additional file 1: Figure S1, S2 partially show red scripts.Fig1Fig. 2

Poly(I:C)_c reduces tumor mass in PDAC concomitant with enhanced T cell activation and reduced suppressive capacity of MDSC. Mice with orthotopic T110299 tumors were treated with poly(I:C)_c twice prior to sacrifice at day 21 after tumor induction. a Tumor weights, tumor cell MHC-I expression and (b) serum cytokine levels. c Frequencies of MDSC populations in spleen and tumor of untreated and poly(I:C)_c-treated mice. d Surface expression profiles of PD-L1 on MDSC subsets. e Frequencies of T cell populations in spleen and tumor of untreated and poly(I:C)_c-treated mice. f-g CD69 and PD-1 surface expression of splenic and tumor-resident T cells. h Representative data of IFN-γ secretion in MDSC / T cell co-cultures, at a ratio of 1:1, following anti-CD3/anti-CD28 mAb-coated beads stimulation for 72 h. i Splenic T cells and MDSC from spleens and tumors of untreated or poly(I:C)_c-treated tumor-bearing mice were isolated and co-cultured with CFSE-labeled T cells in increasing effector (E; MDSC) to target (T; T cell) ratios (E:T) of 0.25:1, 0.5:1 and 1:1 in the presence of anti-CD3/anti-CD28 mAb-coated beads. After 72 h CFSE dilution of CD4⁺ and CD8⁺ T cells was assessed. a-f Data ± SEM is shown for n = 5 to 8 mice per group. g-h Representative graph of three independent experiments. Data± SEM for n = 2 mice per group,unpaired two-sided students t test (*p < 0.05; **p < 0.01)